Mariko Takeda-Morishita

List of Publications by Year
in descending order

35 papers	906 citations	430874 18 h-index	454955 30 g-index
35 all docs	35 docs citations	35 times ranked	931 citing authors

#	Article	IF	Citations
1	In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. Journal of Controlled Release, 2014, 189, 19-24.	9.9	127
2	Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides. Journal of Controlled Release, 2015, 197, 105-110.	9.9	81
3	Mechanistic Study of the Uptake/Permeation of Cell-Penetrating Peptides Across a Caco-2 Monolayer and Their Stimulatory Effect on Epithelial Insulin Transport. Journal of Pharmaceutical Sciences, 2013, 102, 3998-4008.	3.3	61
4	One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 736-743.	4.3	58
5	Effect of an Enhanced Nose-to-Brain Delivery of Insulin on Mild and Progressive Memory Loss in the Senescence-Accelerated Mouse. Molecular Pharmaceutics, 2017, 14, 916-927.	4.6	45
6	Determination of the Optimal Cell-Penetrating Peptide Sequence for Intestinal Insulin Delivery Based on Molecular Orbital Analysis with Self-Organizing Maps. Journal of Pharmaceutical Sciences, 2013, 102, 469-479.	3.3	44
7	Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy. Molecular Pharmaceutics, 2016, 13, 1004-1011.	4.6	41
8	Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4264-E4271.	7.1	39
9	Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction. Scientific Reports, 2018, 8, 17641.	3.3	36
10	Complexation hydrogels as potential carriers in oral vaccine delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 138-142.	4.3	31
11	Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane. AAPS Journal, 2015, 17, 1427-1437.	4.4	29
12	Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form. International Journal of Pharmaceutics, 2016, 510, 304-310.	5.2	29
13	Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 42-51.	4.3	25
14	Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity. Journal of Controlled Release, 2020, 319, 397-406.	9.9	25
15	Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. Drug Metabolism and Pharmacokinetics, 2015, 30, 221-226.	2.2	21
16	Noncovalent Strategy with Cell-Penetrating Peptides to Facilitate the Brain Delivery of Insulin through the Bloodâ€"Brain Barrier. Biological and Pharmaceutical Bulletin, 2018, 41, 546-554.	1.4	20
17	Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems. Journal of Pharmaceutical Sciences, 2016, 105, 2014-2017.	3.3	19
18	Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems. Journal of Pharmaceutical Sciences, 2016, 105, 747-753.	3.3	19

#	ARTICLE	IF	CITATIONS
19	Dependence of Intestinal Absorption Profile of Insulin on Carrier Morphology Composed of Î²-Cyclodextrin-Grafted Chitosan. Molecular Pharmaceutics, 2016, 13, 4034-4042.	4.6	18
20	The in vitro and in vivo study of novel formulation of andrographolide PLGA nanoparticle embedded into gelatin-based hydrogel to prolong delivery and extend residence time in joint. International Journal of Pharmaceutics, 2021, 602, 120618.	5.2	18
21	Safety of the Cell-Penetrating Peptide Penetratin as an Oral Absorption Enhancer. Biological and Pharmaceutical Bulletin, 2015, 38, 144-146.	1.4	17
22	Potential of single cationic amino acid molecule â€œArginineâ€•for stimulating oral absorption of insulin. International Journal of Pharmaceutics, 2017, 521, 176-183.	5.2	17
23	Hydrophobic Amino Acid Tryptophan Shows Promise as a Potential Absorption Enhancer for Oral Delivery of Biopharmaceuticals. Pharmaceutics, 2018, 10, 182.	4.5	17
24	Exploration of the Key Factors for Optimizing the <i>in Vivo</i> Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides. Biological and Pharmaceutical Bulletin, 2018, 41, 239-246.	1.4	12
25	Optimization of the method for analyzing endocytosis of fluorescently tagged molecules: Impact of incubation in the cell culture medium and cell surface wash with glycine-hydrochloric acid buffer. Journal of Controlled Release, 2019, 310, 127-140.	9.9	11
26	Investigation of the Transport Pathways Associated with Enhanced Brain Delivery of Peptide Drugs by Intranasal Coadministration with Penetratin. Pharmaceutics, 2021, 13, 1745.	4.5	11
27	Effects of intestinal luminal contents and the importance of microfold cells on the ability of cell-penetrating peptides to enhance epithelial permeation of insulin. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 155, 77-87.	4.3	10
28	The Effects of Andrographolide on the Enhancement of Chondrogenesis and Osteogenesis in Human Suprapatellar Fat Pad Derived Mesenchymal Stem Cells. Molecules, 2021, 26, 1831.	3.8	9
29	Cell-penetrating Peptide-biodrug Strategy for Oral and Nasal Delivery: Review of Recent Findings. Journal of Experimental and Clinical Medicine, 2012, 4, 198-202.	0.2	7
30	The Intestinal Efflux Transporter Inhibition Activity of Xanthones from Mangosteen Pericarp: An In Silico, In Vitro and Ex Vivo Approach. Molecules, 2020, 25, 5877.	3.8	5
31	Therapeutic effects of anti-amyloid Î² antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimerâ€™s disease mouse model. Drug Delivery and Translational Research, 2022, , 1.	5.8	2
32	Microvillus-Specific Protein Tyrosine Phosphatase SAP-1 Plays a Role in Regulating the Intestinal Paracellular Transport of Macromolecules. Journal of Pharmaceutical Sciences, 2017, 106, 2904-2908.	3.3	1
33	Evaluation of Cell-Penetrating Peptides as Versatile, Effective Absorption Enhancers: Relation to Molecular Weight and Inherent Epithelial Drug Permeability. Pharmaceutical Research, 2020, 37, 182.	3.5	1
34	Recent trends on clinical development of needle-free GLP-1 and insulin delivery systems. Drug Delivery System, 2016, 31, 440-449.	0.0	0
35	Strategy for Peptide Drug Delivery via Nose-to-Brain Transport Pathways: Challenges to Pharmacotherapy for Dementia. Drug Delivery System, 2019, 34, 360-367.	0.0	0